Antibody Drug Conjugates
Antibody drug conjugates (ADCs) continue to change the treatment paradigm of breast cancer and recent regulatory approvals of next generation ADCs are shifting how breast cancer is classified and treated. ADCs combine precision targeting with traditional cytotoxic treatment allowing for the delivery...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Capítulo de libro |
| Lenguaje: | inglés |
| Publicado: |
IntechOpen
2023
|
| Materias: | |
| Acceso en línea: | https://www.intechopen.com/chapters/86728 |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares: Antibody Drug Conjugates
- Antibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer /
- Neoadjuvant Immune Checkpoint Inhibitors and Antibody-Drug Conjugates in Urothelial Carcinoma: Current Evidence and Future Perspectives
- ADCNet: a unified framework for predicting the activity of antibody-drug conjugates
- Effect of Lys-207 of trastuzumab on stability of antibody-drug conjugates bearing linkers based on acetals and thiol-maleimide chemistry
- Antibody-Antigen Binding Events: The Effects of Antibody Orientation and Antigen Properties on the Immunoassay Sensitivity
- Antibody Therapies for Multiple Myeloma